Humacyte

Humacyte Share Count Growth

Year-over-Year Share Count Growth of Humacyte (HUMA) as of Nov 21, 2026.

Share Count Growth

0.00

Last updated:

Year-over-Year Share Count Growth of Humacyte is 2025 0.00 . Year-over-Year Share Count Growth of Humacyte was 2024 0.00 . It decreases by % lower compared to the previous year.

The Humacyte Share Count Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Count Growth
Date
Share Count Growth
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.00 USD
The Humacyte Share Count Growth history
YEARShare Count GrowthYoY
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humacyte Stock analysis

What does Humacyte do? Humacyte, Inc. develops and manufactures off-the-shelf, universally implantable bioengineered human tissues and advanced tissue constructs. The company focuses on human acellular vessels (HAVs) targeting vascular repair, reconstruction, and replacement markets, including vascular trauma, AV access for hemodialysis, peripheral arterial disease, and coronary artery bypass grafting. HAVs are also being developed for pediatric heart surgery and cellular therapies like pancreatic islet cell transplantation for Type 1 diabetes. The company's technology platform uses primary human aortic vascular cells to mimic human physiology. Humacyte's products are sold to healthcare providers and medical institutions for surgical procedures requiring tissue replacement. The vascular repair and hemodialysis markets represent key segments where HAVs address unmet clinical needs. Pediatric heart surgery applications target specialized medical centers, while cellular therapy delivery focuses on diabetes treatment centers. The company's novel manufacturing paradigm enables universal implantability without immune rejection. The firm's revenue streams derive from the sale of HAVs for vascular procedures and their expansion into pediatric and cellular therapy applications. Market segments include vascular surgery, nephrology for hemodialysis access, and endocrinology for diabetes treatment. HAVs are positioned as a solution for patients requiring tissue grafts with reduced risk of rejection compared to traditional methods. Humacyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humacyte stock

On Eulerpool you can find the complete historical development of Year-over-Year Share Count Growth Humacyte since 2006 – with annual values, charts, and detailed analysis.

Share count growth measures the percentage change in shares outstanding. Negative growth indicates buybacks reducing dilution, positive growth signals dilution.

To evaluate Year-over-Year Share Count Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Share Count Growth.

Year-over-Year Share Count Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Share Count Growth's Humacyte historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Humacyte

All Key Metrics — Humacyte